News >

Future of Bladder Cancer Care to Include Immunotherapy Combos

Danielle Bucco
Published: Wednesday, Nov 29, 2017

Petros Grivas, MD

Petros Grivas, MD
Immunotherapy is likely to represent the future of bladder cancer care, especially in combinations with chemotherapy and targeted therapy regimens, according to Petros Grivas, MD.

, Grivas shared insight on the value of combining immunotherapy regimens in the treatment of patients with urothelial carcinoma.

OncLive: Please provide an overview of your presentation on bladder cancer.

Grivas: I discussed the recent updates with immunotherapy, specifically immune checkpoint inhibitors, in the management of patients with advanced urothelial carcinoma. Over the last couple of years, we have seen data with 5 FDA approvals of immune checkpoint inhibitors for the management of patients with platinum-refractory advanced urothelial cancer. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication